ArticleJournal of clinical imaging science2025
Microwave ablation for hepatocellular carcinoma in cirrhotic patients with diuretic-resistant ascites.
Article in Journal of clinical imaging science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The purpose of this study was to evaluate the feasibility, safety, and efficacy of computed tomography (CT)-guided percutaneous microwave ablation (MWA) of liver hepatocellular carcinoma (HCC) lesions in patients with pre-existing diuretic-resistant ascites. There is logical hesitation among clinicians to pursue MWA in these decompensated patients for fear of worsening an already bleak prognosis, but there is limited evidence to justify this behavior. Material and Methods: A retrospective review of HCC treated with percutaneous MWA at a single center was performed. 18 patients who underwent CT-guided MWA with pre-existing diuretic-resistant ascites were identified. A control group of 29 patients who underwent CT-guided MWA without pre-existing diuretic-resistant ascites was identified, which was further narrowed to 18 patients after matching by Model for End-Stage Liver Disease-Sodium score and age. The effectiveness of treatment was compared between the two groups and evaluated by disease-free survival, residual disease, and overall survival over 36 months. Kaplan-Meier curves plotting the survival function were constructed to compare these variables in both groups. Results: MWA was successfully performed in all patients. The probability of survival at 1 year for the ascites and matched control groups were 0.778 and 1.00, respectively ( Conclusion: CT-guided percutaneous MWA for HCC in select patients with pre-existing diuretic-resistant ascites is a feasible, safe, and effective treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.